L01XX27 • arsenic trioxide • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Arsenic trioxide is a medication used in the treatment of acute promyelocytic leukemia (APL), a rare form of leukemia. It works by inducing apoptosis (programmed cell death) in cancer cells and promoting their differentiation into normal cells.
Arsenic trioxide is administered intravenously, usually as part of a combination regimen with other medications such as all-trans retinoic acid (ATRA). It is commonly used in cases of relapsed or refractory APL, as well as a first-line therapy in certain situations.
Common side effects include nausea, fatigue, fever, and elevated liver enzymes. In rare cases, severe complications such as differentiation syndrome or cardiac arrhythmias may occur.
Arsenic trioxide is an essential medication in the treatment of acute promyelocytic leukemia, helping to improve survival rates and patient outcomes.
Substance: arsenic trioxide
Date of last drug list: 01-03-2026
Commercial code: W71667001
Concentration: 2mg / ml
Pharmaceutical form: concentrate for solution for infusion
Quantity: 1
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: TILLOMED MALTA LTD. - MALTA
Holder: TILLOMED MALTA LIMITED - MALTA
Number: 16394/2026/01
Shelf life: 2 years-after packaging for sale;dupa reconstit. sol.-48h la 15-30°C/96h la frigider